| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8268848 | EISAI INC | Cyclopropane compound |
Sep, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(11 years from now) | |
Dayvigo is owned by Eisai Inc.
Dayvigo contains Lemborexant.
Dayvigo has a total of 2 drug patents out of which 0 drug patents have expired.
Dayvigo was authorised for market use on 07 April, 2020.
Dayvigo is available in tablet;oral dosage forms.
Dayvigo can be used as treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Drug patent challenges can be filed against Dayvigo from 07 April, 2024.
The generics of Dayvigo are possible to be released after 21 October, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2025 |
| M(M-293) | Apr 20, 2026 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 07 April, 2024
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Dosage: TABLET;ORAL
DAYVIGO family patents
